The obesity drug retatrutide, which works on three hormone receptors, including the GLP-1 receptor targeted by drugs such as Ozempic, may be useful in treating obstructive sleep apnoea, according to Australian-led research. The research found that in obese or overweight adults with obstructive sleep apnoea, the drug led to fewer apnoeas and hypopneas per hour of sleep compared to placebo. The most common side effects reported were gastrointestinal.